Metastatic Melanoma Treatment in Special Populations

Cancer J. 2024 Mar-Apr 01;30(2):71-78. doi: 10.1097/PPO.0000000000000701.ABSTRACTThis review outlines the most up-to-date metastatic melanoma treatment recommendations and relevant risks for patients with solid organ transplants, patients with renal dysfunction, and patients with preexisting autoimmune conditions. These specific treatment populations were excluded from the original clinical trials, which studied immune checkpoint inhibitors and BRAF/MEK inhibitors in the advanced melanoma setting. We have synthesized the current body of literature, mainly case series and retrospective analyses, to reflect the evidence for the treatment of these special patient populations at present.PMID:38527259 | DOI:10.1097/PPO.0000000000000701
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research